National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2023

Overview

The National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2023 was enacted under the authority of the National Health Act 1953. This determination was made by Nikolai Tsyganov, Assistant Secretary of the Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, who was acting as a delegate of the Minister for Health and Aged Care. The primary objective of this determination is to exercise the Minister's discretion regarding the pricing of certain pharmaceutical items, particularly in relation to price reductions mandated by the Act. The determination specifies which pharmaceutical brands are exempt from price reductions, which are subject to lesser reductions, and the percentage by which some are to be reduced, thereby providing clarity and direction on the implementation of these price adjustments in accordance with the legislative framework established by the National Health Act. The determination addresses the need to ensure that specific pharmaceutical items are priced appropriately while also considering the broader policy objective of maintaining the affordability and accessibility of essential medications within the Australian healthcare system. By delineating which items are exempt from certain reductions and which are subject to modified reductions, the legislation seeks to balance cost-efficiency measures with the imperative to provide necessary treatments at reasonable prices to the public.

Scope and Application

The National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2023 applies to specific pharmaceutical brands as outlined in its schedules. This determination affects the approved ex-manufacturer prices and claimed prices of certain pharmaceutical items, either exempting them from price reductions or applying a lower percentage of price reduction than would otherwise apply. The Act itself, the National Health Act 1953, forms the legislative basis for this determination, empowering the Minister for Health and Aged Care to exercise discretion over price reductions for pharmaceutical items listed under the Pharmaceutical Benefits Scheme (PBS). The application of this determination is geographically limited to Australia, impacting the national pharmaceutical market directly. While the Act does not specify exclusions or exemptions in this particular determination, it is important to note that the scope of application can be extended or restricted through subordinate instruments, which may include regulations or further determinations under the Act. This determination is made under the authority granted by subsections 99ACC(5C) and 99ACF(3) of the National Health Act 1953, and it specifically targets brands of pharmaceutical items, detailing which are exempt from price reductions and which are subject to a reduced percentage. The jurisdictional reach of this determination is Commonwealth-wide, affecting entities involved in the manufacture, supply, and pricing of pharmaceuticals within the Australian market.

Key Provisions

The National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2023, also known as PB 19 of 2023, sets out the details of certain price reductions for pharmaceutical items under the National Health Act 1953. This determination was made by Nikolai Tsyganov, the Assistant Secretary of the Pricing and PBS Policy Branch in the Department of Health and Aged Care, acting as a delegate of the Minister for Health and Aged Care. The provisions of the determination commence on the day it is registered (section 2). The determination is made under subsections 99ACC(5C) and 99ACF(3) of the National Health Act 1953. This legislation specifies certain pharmaceutical items that are subject to different price reduction arrangements. In Schedule 1, certain combination pharmaceutical items are identified as not subject to any price reduction (section 5). Schedule 2 lists pharmaceutical items that are also not subject to a price reduction (section 6). Schedule 3 identifies pharmaceutical items that are subject to a lower percentage price reduction than would otherwise apply (section 7). These determinations impact the prices of specific pharmaceutical brands and their forms and methods of administration. The determination imposes obligations on the entities involved in the pricing and sale of the specified pharmaceutical items. Manufacturers and suppliers must adhere to the price reduction or non-reduction directives as outlined in the schedules. This includes ensuring that the approved ex-manufacturer prices and any claimed prices are adjusted accordingly, in line with the ministerial determination. Failure to comply with these obligations may result in legal consequences. There are no explicit offences, penalties, or consequences for breach outlined in the determination itself. However, any breach of the obligations imposed by this determination may lead to actions under the National Health Act 1953, which could include fines or other penalties as prescribed by the Act. The exact penalties would depend on the specific breach and the provisions of the National Health Act 1953. The determination ensures that the pricing of specified pharmaceutical items is managed in accordance with ministerial discretion, aiming to provide appropriate price adjustments while maintaining the integrity of the national healthcare system.